Results 81 to 90 of about 17,138 (209)

Preparation and Characterization of Zirconia Nanomaterial as a Molybdenum-99 Adsorbent

Atom Indonesia, 2017
The present study deals with the synthesis and characterization of ZrO2 nanomaterial which can be used as an adsorbent for Molybdenum-99 (99Mo). The adsorbent can potentially be utilized as the material for 99Mo/99mTc generator column.
M Marlina, E. Sarmini, H Herlina, S Sriyono, I. Saptiama, H. Setiawan, K Kadarisman   +6 more
doaj   +1 more source

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

A Four‐Week Treatment With Dapagliflozin Is Associated With a Reduction in Insulin‐Stimulated Renal Cortical Glucose Uptake: A Post Hoc Analysis From a Pilot Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8329-8336, September 2026.
ABSTRACT Introduction and Objective Treatment with sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) reduces the risk of both cardiovascular and renal outcomes in type 2 diabetes (T2D). The specific mechanism by which this happens has not yet been clarified.
Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Gian Pio Sorice, Marta Giaccari, Luigi Cappannoli, Umberto Capece, Amelia Splendore, Adriana Avolio, Lorenzo Diego Greco, Patricia Iozzo, Rossana Moroni, Alfredo Pontecorvi, Maria Lucia Calcagni, Francesco Burzotta, Domenico D'Amario, Filippo Crea, Lucia Leccisotti, Francesca Cinti   +18 more
wiley   +1 more source

Structure–activity relationship of 18F-labeled PD-L1-targeting small molecule ligands: impact of radiolabeling strategy on affinity and in vivo performance

EJNMMI Radiopharmacy and Chemistry
Background Immune checkpoint inhibitor therapy addressing the PD-1/PD-L1 axis is a promising approach in cancer treatment. A clinically suitable radiotracer would allow molecular imaging of the temporospatial changes in tumor PD-L1 expression. This could
Fabian Krutzek, Cornelius K. Donat, Sven Stadlbauer   +2 more
doaj   +1 more source

Scanner‐agnostic artificial intelligence approach for fast bone scintigraphy

Journal of Applied Clinical Medical Physics, Volume 27, Issue 8, August 2026.
Abstract Purpose Current bone scintigraphy protocols often demand full‐count, 10–15 min scans to preserve image quality, and existing deep‐learning (DL) denoisers typically need to be retrained or retuned for each camera manufacturer. We introduce a scanner‐agnostic adaptive‐diffusion U‐Net designed to reconstruct diagnostic‐grade images from half‐time
Vinicius de Oliveira Menezes, Cleiton Cavalcante Queiroz, Antônio Augusto Silva Oliveira, Aurílio José dos Santos Filho, Allisson Francisco de Morais, Adriano de Oliveira Vigário, Maria Eduarda Flamini, Felipe Alves Mourato, Tsang Ing Ren, Marcos Antônio Dórea Machado   +9 more
wiley   +1 more source

Evaluation of resazurin phenoxazine dye as a highly sensitive cell viability potency assay for natural killer cell‐derived extracellular vesicle‐based cancer biotherapeutics

Journal of Extracellular Biology
Natural killer cell‐derived extracellular vesicles (NK‐EVs) are candidate biotherapeutics against various cancers. However, standardised potency assays are necessary for a reliable assessment of NK‐EVs' cytotoxicity.
Frederic St‐Denis‐Bissonnette, Shirley Qiu, Sarah E. Cummings, Melanie Kirkby, Yohannes Haile, Sarah Wassmer, Gauri Muradia, Jelica Mehic, Andrew Stalker, Amit Shrestha, Michele Ardolino, Seung‐Hwan Lee, Dylan Burger, Lisheng Wang, Jessie R. Lavoie   +14 more
doaj   +1 more source

Affinity‐Tuned Albumin Hitchhiking Extends the Bioorthogonal Capture Window in Pretargeting Radiotheranostics

Advanced Healthcare Materials, Volume 15, Issue 29, 7 August 2026.
Pharmacokinetic engineering of clickable radioligands was achieved via albumin hitchhiking approach within a pretargeted radiotheranostics delivery platform. This approach reduced rapid renal elimination, expanded bioorthogonal capture window, boosted tumor uptake by ∼3.5‐fold, and improved the tumor‐to‐liver ratio by ∼6‐fold.
Xie He, Nicholas L. Fletcher, Gayathri R. Ediriweera, Yifei Zhu, James Humphries, Christopher B. Howard, Jiazheng Wang, Craig A. Bell, Kristian Kempe, Kristofer J. Thurecht   +9 more
wiley   +1 more source

Classification of tau status with machine learning models in amyloid‐positive cohorts

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Although tau positron emission tomography (PET) imaging is effective for staging tau pathology, it is limited clinically by cost and availability. Machine learning models based on magnetic resonance imaging (MRI)– and amyloid PET–derived features may serve as useful screening tools for tau pathology.
Yun‐Chi Lin, Sheng‐Chieh Chiu, Rebecca Massey, Yu‐Hua Dean Fang, for the Alzheimer's Disease Neuroimaging Initiative   +4 more
wiley   +1 more source

Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters

EJNMMI Radiopharmacy and Chemistry
Background Lutetium-177 (177Lu) theranostics have revolutionized personalized cancer treatment, particularly with FDA-approved therapies like [177Lu]Lu-DOTA-TATE for neuroendocrine tumors and [177Lu]Lu-PSMA for prostate cancer.
William Hunt, Mathew Long, Usama Kamil, Sunil Kellapatha, Wayne Noonan, Peter D. Roselt, Nathan Papa, Brittany Emmerson, Michael S. Hofman, Mohammad B. Haskali   +9 more
doaj   +1 more source

Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

Alzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) frequently co‐occurs with Alzheimer's disease (AD), generating mixed vascular–neurodegenerative phenotypes. Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear. METHODS We studied 231 participants, including 50 patients with CAA (Boston v2.0)
Aida Fernández‐Lebrero, Joan Jiménez‐Balado, Greta García‐Escobar, José Contador, Isabel Estraguès‐Gázquez, Laia Peraferrer‐Montesinos, Rosa María Manero‐Borràs, Laura Ludovica Gramegna, Marc Viles, Ana Rodríguez Campello, Paula Ortiz‐Romero, Marina de Diego, Marta del Campo, Javier Torres‐Torronteras, Esther Jiménez‐Moyano, Helena Blasco‐Forniés, Marc Suárez‐Calvet, Angel Ois, Albert Puig‐Pijoan, Irene Navalpotro‐Gómez   +19 more
wiley   +1 more source